Benoit Rive
Overview
Explore the profile of Benoit Rive including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vieta E, Ahmed N, Arango C, Cleare A, Demyttenaere K, Dold M, et al.
Eur Neuropsychopharmacol
. 2025 Feb;
93:29-39.
PMID: 39923271
Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects...
2.
Young A, Llorca P, Fagiolini A, Falkai P, Cardoner N, Nielsen R, et al.
Br J Psychiatry
. 2024 Dec;
:1-7.
PMID: 39618237
Background: In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release. Aims: To determine the robustness of the ESCAPE-TRD results...
3.
Oliveira-Maia A, Rive B, Godinov Y, Mulhern-Haughey S
Front Psychiatry
. 2024 Oct;
15:1459633.
PMID: 39435126
Introduction: Treatment resistant depression (TRD) affects approximately 10-30% of patients with major depressive disorder, and most patients with TRD do not respond to real-world treatments (RWT). Treatment with esketamine nasal...
4.
Oliveira-Maia A, Morrens J, Rive B, Godinov Y, Cabrieto J, Perualila N, et al.
Front Psychiatry
. 2023 Nov;
14:1250980.
PMID: 38025433
Background: Treatment resistant depression (TRD) affects 10-30% of patients with major depressive disorder. In 4-week trials, esketamine nasal spray (NS) was efficacious vs. placebo when both were initiated in addition...
5.
Oliveira-Maia A, Rive B, Morrens J, Godinov Y, Cabrieto J, Perualila N, et al.
Front Psychiatry
. 2023 Nov;
14:1250987.
PMID: 38025416
Background: The efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to...
6.
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu D, et al.
N Engl J Med
. 2023 Oct;
389(14):1298-1309.
PMID: 37792613
Background: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low...
7.
Morrens J, Mathews M, Popova V, Borentain S, Rive B, Gonzalez Martin Moro B, et al.
Neuropsychiatr Dis Treat
. 2022 Jun;
18:1127-1132.
PMID: 35707064
Background: This post-hoc analysis evaluated the agreement between Clinical Global Impressions-Severity (CGI-S) score- and Montgomery-Åsberg Depression Rating Scale (MADRS) total score-based assessment of response in patients with treatment-resistant depression (TRD)...
8.
Jaffe D, Rive B, Denee T
Neuropsychiatr Dis Treat
. 2019 Sep;
15:2257-2271.
PMID: 31496708
Background: Suicidal ideation (SI) is an associated risk of depression, affecting 30-40% of the depressed population. However, there is a paucity of studies investigating the impact of SI in Europe....
9.
Jaffe D, Rive B, Denee T
BMC Psychiatry
. 2019 Aug;
19(1):247.
PMID: 31391065
Background: A patient is considered to suffer from treatment resistant depression (TRD) when consecutive treatment with two products of different pharmacological classes, used for a sufficient length of time at...
10.
Lam R, Lamy F, Danchenko N, Yarlas A, White M, Rive B, et al.
Neuropsychiatr Dis Treat
. 2018 Nov;
14:2861-2877.
PMID: 30464471
Background: Although depression and cognitive dysfunction are connected, limited tools exist to capture the patient's perspective on cognitive dysfunction and its impact on major depressive disorder (MDD). We report results...